Mizuho Securities Reiterates Neutral as Quest Diagnostics (DGX) Announces Optum Collaboration
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Mizuho Securities reiterated a Neutral rating and $86.00 price target on Quest Diagnostics (NYSE: DGX) following announced collaboration with Optum.
Analyst Ann Hynes commented, "DGX and Optum announced this morning a wide-ranging, long-term relationship that includes 1) A revenue cycle collaboration where DGX's revenue cycle management (RCM) operations and its 2,400 employees will become part of Optum360 2) DGX will become Optum’s primary partner for member biometric screening services that Optum provides and 3) the companies will work to increase the use of diagnostic information services, such as data analytics, population health insights and connectivity solutions."
Shares of Quest Diagnostics closed at $82.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pivotal Research Downgrades Kroger (KR) to Hold
- Mizuho Securities Adjusts Estimates Following Gap, Inc. (GPS) Comp Miss
- Drexel Hamilton Raises Price Target on Workday (WDAY) Following 3Q Beat
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!